Taylor RP - Search Results

1

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.

Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Beum PV, et al. Among authors: taylor rp. J Immunol. 2008 Dec 1;181(11):8120-32. doi: 10.4049/jimmunol.181.11.8120. J Immunol. 2008. PMID: 19018005

2

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP. Kennedy AD, et al. Among authors: taylor rp. Blood. 2003 Feb 1;101(3):1071-9. doi: 10.1182/blood-2002-03-0876. Epub 2002 Sep 5. Blood. 2003. PMID: 12393727 Free article.

3

B cell complement receptor 2 transfer reaction.

Lindorfer MA, Jinivizian HB, Foley PL, Kennedy AD, Solga MD, Taylor RP. Lindorfer MA, et al. Among authors: taylor rp. J Immunol. 2003 Apr 1;170(7):3671-8. doi: 10.4049/jimmunol.170.7.3671. J Immunol. 2003. PMID: 12646632

4

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. Kennedy AD, et al. Among authors: taylor rp. J Immunol. 2004 Mar 1;172(5):3280-8. doi: 10.4049/jimmunol.172.5.3280. J Immunol. 2004. PMID: 14978136

5

Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.

Beum PV, Kennedy AD, Taylor RP. Beum PV, et al. Among authors: taylor rp. J Immunol Methods. 2004 Jun;289(1-2):97-109. doi: 10.1016/j.jim.2004.03.012. J Immunol Methods. 2004. PMID: 15251416

6

Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice.

Whipple EC, Shanahan RS, Ditto AH, Taylor RP, Lindorfer MA. Whipple EC, et al. Among authors: taylor rp. J Immunol. 2004 Aug 15;173(4):2297-306. doi: 10.4049/jimmunol.173.4.2297. J Immunol. 2004. PMID: 15294942

7

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.

Beum PV, Kennedy AD, Li Y, Pawluczkowycz AW, Williams ME, Taylor RP. Beum PV, et al. Among authors: taylor rp. J Immunol Methods. 2004 Nov;294(1-2):37-42. doi: 10.1016/j.jim.2004.08.004. J Immunol Methods. 2004. PMID: 15604014

8

Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.

DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP. DiLillo DJ, et al. Among authors: taylor rp. Mol Immunol. 2006 Mar;43(7):1010-9. doi: 10.1016/j.molimm.2005.05.003. Epub 2005 Jun 14. Mol Immunol. 2006. PMID: 15961157

9

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.

Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. Beum PV, et al. Among authors: taylor rp. J Immunol. 2006 Feb 15;176(4):2600-9. doi: 10.4049/jimmunol.176.4.2600. J Immunol. 2006. PMID: 16456022

10

Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.

Beum PV, Lindorfer MA, Hall BE, George TC, Frost K, Morrissey PJ, Taylor RP. Beum PV, et al. Among authors: taylor rp. J Immunol Methods. 2006 Dec 20;317(1-2):90-9. doi: 10.1016/j.jim.2006.09.012. Epub 2006 Oct 10. J Immunol Methods. 2006. PMID: 17067631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters